trending Market Intelligence /marketintelligence/en/news-insights/trending/pa-Hshv0LZE4nIqEVZM5zA2 content esgSubNav
In This List

Glenmark secures US FDA approval for another generic hypertension drug

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Glenmark secures US FDA approval for another generic hypertension drug

Glenmark Pharmaceuticals Ltd. secured U.S. Food and Drug Administration approval to market a generic version of Allergan PLC's hypertension drug Bystolic.

Glenmark will launch its Nebivolol tablets three months before Bystolic's patent expires as part of a settlement agreement with Allergan.

Bystolic generated annual sales of $1 billion in the 12-month period ending March 2017, according to IMS Health Holdings Inc. data.

Glenmark Pharmaceuticals also recently secured U.S. FDA approval to market a generic version of Benicar, Daiichi Sankyo Co. Ltd.'s hypertension drug.